SEC Form 4 · accession 0001179110-17-012291
ACCELERON PHARMA INC · XLRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Rovaldi
Officer — SVP, Program Mgmt and Ops
Period of report
Sep 12, 2017
Accepted (ET)
Sep 14, 2017 · 5:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001280600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 12, 2017 | S | 12,735 | $38.32 | D | 28,232 | D | |
| Common StockF3 | Sep 12, 2017 | S | 1,165 | $39.30 | D | 27,067 | D | |
| Common Stock | Sep 12, 2017 | S | 100 | $39.96 | D | 26,967 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.78 to $38.77 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.85 to $39.82 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.